Table 3. Univariate and Multivariate Results Assessing Correlation With Loss to Follow-up.
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Age | 1.021 (0.999-1.044) | .07 | 1.065 (1.029-1.105) | <.001 |
| White race/ethnicity | 1.391 (0.708-2.950) | .36 | 4.006 (1.587-11.055) | .005 |
| Women | 0.828 (0.499-1.375) | .46 | 0.841 (0.465-1.524) | .57 |
| Live independently (vs assisted living) | 0.288 (0.142-0.588) | <.001 | 0.296 (0.129-0.678) | <.001 |
| Live alone | 1.749 (1.018-2.977) | .04 | 1.831 (0.974-3.429) | .06 |
| Finished college or completed advanced degree | 0.613 (0.367-1.017) | .06 | NA | NA |
| Personally know someone infected with COVID-19 | 0.971 (0.516-1.756) | .92 | NA | NA |
| Location (Emory) | 1.506 (0.878-2.657) | .15 | 1.678 (0.899-3.220) | .11 |
| Received treatment at satellite clinic | 1.160 (0.671-1.974) | .59 | NA | NA |
| Self-reported fair or poor health | 2.249 (1.310-4.055) | .003 | 2.417 (1.293-4.512) | .006 |
| No. of comorbidities | 1.438 (1.144-1.821) | .002 | NA | NA |
| Treatment indication of DR (vs AMD) | 1.704 (1.006-2.865) | .046 | 8.130 (3.367-20.408) | <.001 |
| Treated eye ≥3 lines better vision than fellow eye, or treated in both eyes | 0.773 (0.464-1.280) | .32 | NA | NA |
| Self-reported fair, poor, or very poor vision | 2.266 (1.310-4.055) | .004 | NA | NA |
| Very or moderately concerned for permanent vision loss due to missed appointments from pandemic | 1.607 (0.969-2.684) | .07 | 1.755 (0.969-3.219) | .07 |
| Perceived extremely likely or likely to be exposed to COVID-19 at eye clinic | 4.338 (2.300-8.200) | <.001 | 3.900 (1.831-8.403) | <.001 |
| Willing to accept a maximum of 1:100 000 or less risk of exposure to maintain vision | 1.220 (0.700-2.089) | .47 | NA | NA |
Abbreviations: AMD, age-related macular degeneration; COVID-19, coronavirus disease 2019; DR, diabetic retinopathy; NA, not applicable; OR, odds ratio.